Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S Mathews Ave, Urbana, IL 61801, USA.
Chembiochem. 2022 Sep 5;23(17):e202200260. doi: 10.1002/cbic.202200260. Epub 2022 Jul 19.
Small molecule targeting of DNA and RNA sequences has come into focus as a therapeutic strategy for diseases such as myotonic dystrophy type 1 (DM1), a trinucleotide repeat disease characterized by RNA gain-of-function. Herein, we report a novel template-selected, reversible assembly of therapeutic agents in situ via aldehyde-amine condensation. Rationally designed small molecule targeting agents functionalized with either an aldehyde or an amine were synthesized and screened against the target nucleic acid sequence. The assembly of fragments was confirmed by MALDI-MS in the presence of DM1-relevant nucleic acid sequences. The resulting hit combinations of aldehyde and amine inhibited the formation of r(CUG) in vitro in a cooperative manner at low micromolar levels and rescued mis-splicing defects in DM1 model cells. This reversible template-selected assembly is a promising approach to achieve cell permeable and multivalent targeting via in situ synthesis and could be applied to other nucleic acid targets.
小分子靶向 DNA 和 RNA 序列已成为肌强直性营养不良 1 型 (DM1) 等疾病的治疗策略,该疾病是一种由 RNA 获得性功能引起的三核苷酸重复疾病。在此,我们报告了一种新的模板选择方法,通过醛胺缩合在原位可逆组装治疗剂。设计合理的小分子靶向剂用醛或胺官能化,并针对靶核酸序列进行筛选。在存在与 DM1 相关的核酸序列的情况下,通过 MALDI-MS 确认了片段的组装。醛和胺的组合以协同方式在低微摩尔水平下抑制 r(CUG)的形成,并在 DM1 模型细胞中挽救错配剪接缺陷。这种可还原的模板选择组装是一种很有前途的方法,可以通过原位合成实现细胞通透性和多价靶向,并可应用于其他核酸靶标。